Peptron, Inc. (KOSDAQ:087010)

South Korea flag South Korea · Delayed Price · Currency is KRW
280,000
-13,500 (-4.60%)
Aug 1, 2025, 3:30 PM KST
-4.60%
Market Cap6.52T
Revenue (ttm)4.30B
Net Income (ttm)-21.32B
Shares Out23.30M
EPS (ttm)-994.71
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume140,395
Average Volume255,310
Open288,500
Previous Close293,500
Day's Range275,000 - 290,500
52-Week Range39,845 - 315,000
Beta0.73
RSI59.71
Earnings Daten/a

About Exscientia

Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 087010
Full Company Profile

Financial Performance

In 2024, Peptron's revenue was 3.15 billion, a decrease of -5.68% compared to the previous year's 3.34 billion. Losses were -22.03 billion, 38.4% more than in 2023.

Financial numbers in EUR Financial Statements

News

There is no news available yet.